ROR1 as an Immunotherapeutic Target for Inducing Antitumor Helper T Cell Responses Against Head and Neck Squamous Cell Carcinoma
Authors:
- Ryosuke SatoRSRyosuke Sato
- Hidekiyo YamakiHYHidekiyo Yamaki
- Takahiro InoueTITakahiro Inoue
- Shota SakaueSSShota Sakaue
- Hisataka OminatoHOHisataka Ominato
- Risa WakisakaRWRisa Wakisaka
- Hiroki KomatsudaHKHiroki Komatsuda
- Michihisa KonoMKMichihisa Kono
- Kenzo OharaKOKenzo Ohara
- Akemi KosakaAKAkemi Kosaka
- Takayuki OhkuriTOTakayuki Ohkuri
- Toshihiro NagatoTNToshihiro Nagato
Open Access
Abstract
Background/Objectives: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer, with limited responsiveness to immune checkpoint inhibitors (ICIs). Cancer vaccine therapy is a promising novel immunotherapeutic approach that stimulates tumor-specific T cells. Receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is overexpressed in malignant tumors but minimally expressed in normal tissues, presents a promising target for immunotherapy. This study aimed to evaluate ROR1 as a target for helper T lymphocyte (HTL)-based peptide vaccine immunotherapy in HNSCC. Methods: ROR1 expression in HNSCC tissues was assessed by immunohistochemistry. A novel ROR1-derived epitope (ROR1403–417) was identified and used to generate ROR1-reactive HTLs. Functional assays measuring IFN-γ and granzyme B secretion, as well as direct cytotoxicity, were performed. The effects of ICIs on HTL activity were also examined. The presence of ROR1-reactive T cells in the peripheral blood of patients with HNSCC was evaluated. Results: ROR1 positivity rates in HNSCC tissues were significantly higher (80.0%) than those in healthy controls (16.7%), and high ROR1 expression correlated with advanced clinical stages. HTL lines recognized the ROR1403–417 peptide in a human leukocyte antigen (HLA)-DR-restricted manner, secreted effector cytokines, and exhibited direct cytotoxicity against ROR1+ tumor cells. Dual PD-L1/PD-L2 blockade further enhanced HTL responses. ROR1-reactive T cells were detected in the peripheral blood of patients with HNSCC. Conclusions: ROR1 represents a promising target for immunotherapy in HNSCC. The ROR1403–417 peptide can elicit ROR1-reactive HTLs that exhibit antitumor responses against HNSCC cell lines, which can be enhanced by ICIs. These findings support the potential of ROR1-targeted peptide vaccine therapy for HNSCC.Keywords
Funding Information
- JSPS KAKENHI (24K19743, 23K08977)
This publication has 48 references indexed in Scilit:
- Tumor-associated antigen prediction using a single-sample gene expression state inference algorithmCell Reports Methods, 2024
- Therapeutic advances in the targeting of ROR1 in hematological cancersCell Death Discovery, 2024
- Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD‐L1 and PD‐L2Head & Neck, 2024
- Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancerHead & Neck, 2024
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyThe Lancet, 2024
- Evolving landscape of PD-L2: bring new light to checkpoint immunotherapyBritish Journal of Cancer, 2022
- Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public HealthThe Oncologist, 2021
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- ROR1 expression is not a unique marker of CLLHematological Oncology, 2011
- Granzymes in cancer and immunityCell Death & Differentiation, 2010